Activated Platelet Rich Plasma as a New Treatment Modality for Cataract Disorders: In Vivo Study

Introduction: Cataract is the main cause of visual impairment and vision loss in world, where 33% world's population has decreased due to cataracts. This study aims explore role platelet-rich plasma (PRP) inhibiting pro-inflammatory cytokine interleukin-1ß, thereby triggering tissue repair cataract cases vivo study.
 Methods: an experimental with a post-test-only approach control group design. A total 30 rats (Rattus norvegicus) Wistar strain was included this (male, 150-200 g, 8-10 weeks). The were divided into 3 groups, P1 (the that not induced by treated plasma), P2 given 10 uL intraocular saline injection), P3 injection plasma). Plasma uL).
 Results: results showed received treatment significant decrease IL-1B levels when compared but without PRP administration (p<0.05).
 Conclusion: Activated potential as new therapeutic modality conditions through inhibition chronic inflammatory response studies.